Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility

Aim Liraglutide treatment is associated with gallbladder‐related disorders and has been shown to delay postprandial gallbladder refilling. The gut hormones cholecystokinin (CCK), fibroblast growth factor 19 (FGF19) and glucagon‐like peptide 2 (GLP‐2), are known to regulate gallbladder motility and m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2023-06, Vol.25 (6), p.1632-1637
Hauptverfasser:	Nerild, Henriette H., Brønden, Andreas, Gether, Ida M., Hellmann, Pernille H., Baekdal, Mille, Gillum, Matthew P., Svenningsen, Jens S., Hartmann, Bolette, Rathor, Naveen, Kudiyanur Muniraju, Hanna Angelene, Rehfeld, Jens F., Holst, Jens J., Vilsbøll, Tina, Sonne, David P., Knop, Filip K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antidiabetics Blood Glucose - metabolism Body Mass Index Cholecystokinin clinical trial Diabetes Mellitus, Type 2 - complications Double-Blind Method Female Fibroblast growth factors Gallbladder Gallbladder - metabolism Gastric motility GLP1 GLP‐1 analogue Glucagon Humans incretin physiology incretin therapy liraglutide Liraglutide - pharmacology Liraglutide - therapeutic use Male Middle Aged Motility Obesity Obesity - complications Placebos Postprandial Period
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!